Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON ...

Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

United Healthcare Insurance Co. struck a deal to resolve three proposed class actions saying it wrongly refused to cover a ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Combining microbeam radiotherapy with targeted radiosensitizers could treat tumours while sparing normal brain tissues ...

Hadron therapy is a state-of-the-art radiotherapy technique that uses proton or ion beams to target tumoral cells, while ...

A 2D projection of a particle accelerator beam, computer-generated based on generative diffusion. The process is adaptively ...

The state’s Office of Health Strategy has agreed with Danbury Proton, allowing the organization to open a $72 million proton ...